Patient outcome and survival. (A) Evaluation of the leukemic blast infiltration in the BM before and 4 weeks after infusion of CD19-CAR_Lenti T cells, by flow cytometry. (B) Swimmer plot of all patients treated in the clinical trial. The survival of the patients was evaluated, in terms of OS and EFS for the whole cohort of patients, either without (C-D) or with censoring for HSCT (E-F), for the patients treated at the DL of 3 × 10⁶ CAR⁺ cells per kg (G-H) and for the cohort of patients treated for a VHR first relapse (I,J).